Pharming Group N.V. ( (PHGUF) ) has released its Q2 earnings. Here is a breakdown of the information Pharming Group N.V. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pharming Group N.V. is a global biopharmaceutical company based in Leiden, Netherlands, focusing on innovative treatments for rare diseases, including small molecules and biologics. In its latest earnings report, Pharming Group reported a strong financial performance for the second quarter and first half of 2025, with a 26% increase in total revenues to $93.2 million, driven by significant growth in its RUCONEST® and Joenja® products. Key highlights include a 28% rise in RUCONEST® revenue to $80.4 million and a 15% increase in Joenja® revenue to $12.8 million, alongside a turnaround in operating profit from a loss of $3.1 million in the previous year to a profit of $10.8 million. The company also raised its 2025 total revenue guidance to between $335 million and $350 million. Pharming Group’s strategic initiatives include the submission of a new drug application for leniolisib in Japan and ongoing clinical trials for leniolisib in larger primary immunodeficiency indications. Looking ahead, Pharming Group remains optimistic about its growth prospects, with plans to expand its patient base for Joenja® and advance its clinical pipeline, despite challenges such as U.S. tariffs.